Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
49 hedge funds and large institutions have $33.6M invested in Codiak BioSciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 21 closing their positions.
158% more call options, than puts
Call options by funds: $31K | Put options by funds: $12K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less funds holding
Funds holding: 62 → 49 (-13)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
57% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 21
61% less capital invested
Capital invested by funds: $86.5M → $33.6M (-$52.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$407K |
| 3 |
Millennium Management
New York
|
+$404K |
| 4 |
Renaissance Technologies
New York
|
+$284K |
| 5 |
E
Ergoteles
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
-$6.15M |
| 2 |
BlackRock
New York
|
-$2.49M |
| 3 |
State Street
Boston,
Massachusetts
|
-$923K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$635K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$476K |
CDAK Hedge Fund Activity: Q2 2022 in Review
49 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q2 2022, worth a combined $33.6M — down 61% from $86.5M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CDAK and 9 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.1M. The largest seller was Alaska Permanent Fund, exiting entirely with an estimated $6.15M sold.
- 49 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q2 2022, down from 62 in Q1 2022.
- Funds reported $33.6M of Codiak BioSciences, Inc. Common Stock stock for Q2 2022, down 61% quarter-over-quarter.
- 9 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q2 2022 and 21 closed out, a net change of -12 holders.
- The largest Codiak BioSciences, Inc. Common Stock buyer in Q2 2022 was Laurion Capital Management, an estimated $1.1M added.
- The largest Codiak BioSciences, Inc. Common Stock seller in Q2 2022 was Alaska Permanent Fund, an estimated $6.15M sold.
Based on aggregated 13F filings for Q2 2022.